Join Growin Stock Community!

Mainz biomed b.v.MYNZ.US Overview

US StockHealthcare
(No presentation for MYNZ)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

MYNZ AI Insights

MYNZ Overall Performance

MYNZ AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

MYNZ Recent Performance

-3.22%

Mainz biomed b.v.

0.05%

Avg of Sector

-0.31%

S&P500

MYNZ PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

MYNZ Key Information

MYNZ Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

MYNZ Profile

Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.

Price of MYNZ

MYNZ FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

MYNZ Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-5.19
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
10.43
PB Ratio
2.61
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
68.55%
Net Margin
-2847.37%
Revenue Growth (YoY)
1.48%
Profit Growth (YoY)
12.76%
3-Year Revenue Growth
14.27%
3-Year Profit Growth
22.57%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-5.19
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
10.43
PB Ratio
2.61
Price-to-FCF
-
Gross Margin
68.55%
Net Margin
-2847.37%
Revenue Growth (YoY)
1.48%
Profit Growth (YoY)
12.76%
3-Year Revenue Growth
14.27%
3-Year Profit Growth
22.57%

  • When is MYNZ's latest earnings report released?

    The most recent financial report for Mainz biomed b.v. (MYNZ) covers the period of 2025Q2 and was published on 2025/06/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating MYNZ's short-term business performance and financial health. For the latest updates on MYNZ's earnings releases, visit this page regularly.

  • How much debt does MYNZ have?

    As of the end of the reporting period, Mainz biomed b.v. (MYNZ) had total debt of 1.95M, with a debt ratio of 0.2. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does MYNZ have?

    At the end of the period, Mainz biomed b.v. (MYNZ) held Total Cash and Cash Equivalents of 1.91M, accounting for 0.19 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.